Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01701245
Recruitment Status : Completed
First Posted : October 5, 2012
Results First Posted : April 25, 2016
Last Update Posted : April 25, 2016
Sponsor:
Information provided by (Responsible Party):
ElectroCore INC

Tracking Information
First Submitted Date  ICMJE October 3, 2012
First Posted Date  ICMJE October 5, 2012
Results First Submitted Date September 30, 2015
Results First Posted Date April 25, 2016
Last Update Posted Date April 25, 2016
Study Start Date  ICMJE October 2012
Actual Primary Completion Date March 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 23, 2016)
A Change in the Frequency of Cluster Headache Attacks Per Week [ Time Frame: 4 weeks ]
The primary endpoint is the reduction in mean number of CH attacks per week. The number of CH attacks will be calculated as the sum of all attacks over the days in the run-in period and divided by the number of weeks, respectively for the last 14 days of treatment during the randomised phase. The reduction will then be the number of CH attacks during treatment period (last 14 days of the randomized treatment period) - number of CH attacks during run-in.
Original Primary Outcome Measures  ICMJE
 (submitted: October 3, 2012)
Decrease frequency of cluster headache attacks per week [ Time Frame: 4 weeks ]
The primary endpoint is the reduction in mean number of CH attacks per week. The number of CH attacks will be calculated as the sum of all attacks over the days in the run-in period and divided by the number of weeks, respectively for the last 14 days of treatment during the randomised phase. The reduction will then be the number of CH attacks during treatment period (last 14 days of the randomized treatment period) - number of CH attacks during run-in.
Change History Complete list of historical versions of study NCT01701245 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 23, 2016)
  • Pain Relief of Headache Attacks [ Time Frame: baseline (2 weeks) and random period(last 2 weeks) ]
    The median pain during baseline (2 weeks) will be compared with the last 14 days of the treatment period Scale 0-4 0= no pain
    1. mild pain
    2. moderate pain
    3. severe pain
    4. very severe pain
  • Adverse Events [ Time Frame: 10 weeks ]
    The frequency of device effects will be compared between the two treatment groups. Only effects which are new after baseline or have increased severity after baseline will be used in the comparison.
  • EQ-5D-3L (EuroQoL 5 Questions and 3 Answering Levels) and a VAS (Visual Analogue Scale) [ Time Frame: 10 weeks (baseline 2 weeks, random 4 weeks and open label 4 weeks) ]
    The EQ-5D-3L (EuroQoL 5 questions and 3 answering levels) during the run-in period will be compared with the EQ-5D-3L during the treatment period. And treatment period will be compared to open label. Rating of questions Level 1 no problems Level 2 some problems Level 3 Significant problems Worst case is 15 points and best case is 5 points using index Visual analogue scale VAS 0-100 where 0 is the worst imaginable health state and 100 the best imaginable health state
Original Secondary Outcome Measures  ICMJE
 (submitted: October 3, 2012)
  • Pain Relief of Headache Attacks [ Time Frame: 10 weeks ]
    The mean pain during run-in will be compared with both the pain relief the last 14 days of the treatment period and the pain relief during the whole treatment period.
  • Adverse Events [ Time Frame: 10 weeks ]
    The frequency of device effects will be compared between the two treatment groups. Only effects which are new after baseline or have increased severity after baseline will be used in the comparison.
  • EQ-5D-3L [ Time Frame: 10 weeks ]
    The EQ-5D-3L during the run-in period will be compared with the EQ-5D-3L during the treatment period.
Current Other Outcome Measures  ICMJE Not Provided
Original Other Outcome Measures  ICMJE Not Provided
 
Descriptive Information
Brief Title  ICMJE Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care
Official Title  ICMJE A Randomized, Multicenter Study for the Prevention and Acute Treatment of Chronic Cluster Headache Using Gammacore, Versus Standard of Care.
Brief Summary Subjects enrolled into this 10 week study will for the first two weeks document the number of cluster headaches and the means of treating (medication) of these attacks. Subjects will then be randomized to into either two groups. The first group is continuing with standard of care and the second group is treatment with the investigational device (GammaCore) for a period of 4 weeks. After this 4 week period, all subjects will treat with the GammaCore for another 4 week period. It is hypothesized the the treatment group will have a reduction in mean cluster headaches per week by 50% compared to the standard of care group.
Detailed Description

The study is a prospective randomized controlled multi-center investigation designed for comparison of two parallel groups, GammaCore® (active treatment) and Standard of Care, SoC, (control). The study period begins with a 2 week run-in period, followed by a 4 week comparative period when the subjects are randomized to either active treatment or control 1:1. The comparative period will be followed by a period where all subject will receive GammaCore® for 4 weeks.After the subject signed the Consent Form for participation the baseline (visit1) data will be collected. Subject will be informed how to complete the 2 week diary during the run-in period During the run-in period, all subjects will use stable SoC according to their individual prescriptions. The subject will record as CH attack regarding duration and frequency and the use of medication and oxygen.

Once subjects have finalized the run-in period, they are randomized to continue in 4 weeks comparative period. During this period, the control group continues with stable SoC and the active group is provided with a GammaCore® device for prophylactic and acute treatment in addition to the stable SoC Subjects stimulate 3 x 2 times daily as part of the prophylactic treatment regimen (cervical vagal nerve). Three 90 second stimulations are self-administered by the subject with 5 minutes between each stimulation on the right side of the neck.

This preventive stimulation regimen is performed:

  • First Daily Treatment - within 1 hour of waking
  • Second Daily Treatment - 7-10 hours following the first daily treatment

Acute CH attack:

  • 3 x 90 second treatments consecutively at the onset of pain or symptoms. If the attack is not aborted within 15 minutes the subject should be informed to take SOC abortive medication.
  • If an acute cluster headache attack is treated with the GammaCore® device, the subject will try to work within the preventive treatment window to avoid a preventive treatment in the 2-hour refractory period following the acute treatment.

A total of minimally 6 stimulations for the preventive part and as needed for the acute attacks. The active group also continues with the stable SoC during the entire 4 weeks period. Both groups record all CH attacks in the diary together with medication and oxygen use. All adverse events shall also be recorded in the diary.

The end of the 4 week comparative period marks the completion of the randomized part of the study, however all subjects are provided the option to continue to a 4 week GammaCore® treatment with the same stimulation parameter as during the 4 week randomization period. All subjects randomized to the SoC group will receive training.

During the entire study period, subjects are allowed to take rescue medication including oxygen inhalation for abortion of CH attacks. The amount and doses of the medication and oxygen are recorded in the diary.

Study Type  ICMJE Interventional
Study Phase Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Chronic Cluster Headache
Intervention  ICMJE Device: GammaCore
vagal stimulation
Study Arms
  • No Intervention: Standard of care
    No intervention, standard of care
  • Active Comparator: GammaCore
    Three stimulation treatments 2x/day 7 to 10 hours apart from one another. In addition, three stimulation treatments at the time of onset of symptoms of a headache attack.
    Intervention: Device: GammaCore
Publications * Morris J, Straube A, Diener HC, Ahmed F, Silver N, Walker S, Liebler E, Gaul C. Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache. J Headache Pain. 2016;17:43. doi: 10.1186/s10194-016-0633-x. Epub 2016 Apr 22.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 23, 2016)
97
Original Estimated Enrollment  ICMJE
 (submitted: October 3, 2012)
80
Actual Study Completion Date October 2014
Actual Primary Completion Date March 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

1. Signed Informed Consent Form 2. Subjects between the age of 18-70, both genders 3. Subjects diagnosed with chronic cluster headache for at least 1 year, without remission periods or with remission periods lasting <1 month, in accordance with the ICHD-II classification criteria (2ndEd):

a. At least 5 attacks fulfilling the following criteria: i. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15-180 minutes if untreated ii. Headache is accompanied by at least 1 of the following:

  1. Ipsilateral conjunctival injection and/or lacrimation
  2. Ipsilateral nasal congestion and/or rhinorrhea
  3. Ipsilateral eyelid oedema
  4. Ipsilateral forehead and facial sweating
  5. Ipsilateral miosis and/or ptosis
  6. A sense of restlessness or agitation iii. Attacks have a frequency from 1 every other day to 8 per day and are not attributed to another disorder iv. Attacks recur over > 1 year without remission periods or with remission periods lasting < 1 month.

4. Has minimum mean attack frequency of 4 CH attacks per week. 5. Is able to distinguish CH from other headaches (i.e. tension-type headaches).

6. Is capable of completing headache pain self-assessments. 7. Agrees to use the GammaCore® device as intended and follow all of the requirements of the study, including follow-up visit requirements.

8. Is willing to keep all concomitant medication stable during the entire study period.

9. Women of child-bearing potential must use 2 methods of contraceptive i.e. hormones and condom.

Exclusion Criteria:

  1. Is currently taking CH prophylactic medication for indications other than CH which in the opinion of the clinician may interfere with the study
  2. Has had a change in type or dosage of prophylactic headache medications < 1 month prior to enrollment
  3. Has a history of intracranial or carotid aneurysm, intracranial hemorrhage, brain tumors or significant head trauma.
  4. Has a lesion (including lymphadenopathy), dysaesthesia, previous surgery or abnormal anatomy at the GammaCore® treatment site.
  5. Has other significant pain problem that might confound the study assessments in the opinion of the investigator.
  6. Has known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g. bruits or history of TIA or CVA), congestive heart failure (CHF), known severe coronary artery disease or recent myocardial infarction (within 5years).
  7. Has had a previous unilateral or bilateral vagotomy.
  8. Has uncontrolled high blood pressure.
  9. Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
  10. Has a history of carotid endarterectomy or vascular neck surgery on the right side.
  11. Has been implanted with metal cervical spine hardware or has a metallic implant near the GammaCore® stimulation site.
  12. Has a history, the last 12 month, of syncope.
  13. Has a history, the last 12 month of seizures.
  14. Has a known history or suspicion of substance abuse or addiction, or overuse of acute headache medication for headaches other than CH.
  15. Has psychiatric or cognitive disorder and/or behavioral problems which in the opinion of the investigator may interfere with the study
  16. In the opinion of the investigator the subject is incapable of operating the GammaCore® device as intended and performing the data collection procedures.
  17. Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.
  18. Woman who are pregnant or lactating.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Germany,   Italy,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01701245
Other Study ID Numbers  ICMJE GC-002
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD: No
Plan Description: Not planned to share individual data
Responsible Party ElectroCore INC
Study Sponsor  ICMJE ElectroCore INC
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Charly Gaul, Dr med Migräne- und Kopfschmerzklinik Königstein
PRS Account ElectroCore INC
Verification Date March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP